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Abstract
Background: Nasopharyngeal carcinoma (NPC) is one of the most common cancers in southern
China. In addition to environmental factors such as Epstein-Barr virus infection and diet, genetic
susceptibility has been reported to play a key role in the development of this disease. The x-ray
repair cross-complementing group 1 (XRCC1) gene is important in DNA base excision repair. We
hypothesized that two common single nucleotide polymorphisms of XRCC1 (codons 194
Arg→Trp and 399 Arg→Gln) are related to the risk of NPC and interact with tobacco smoking.
Methods: We sought to determine whether these genetic variants of the XRCC1 gene were
associated with the risk of NPC among the Cantonese population in a hospital-based case control
study using polymerase chain reaction-restriction fragment length polymorphism analysis. We
conducted this study in 462 NPC patients and 511 healthy controls.
Results:  After adjustment for sex and age, we found a reduced risk of developing NPC in
individuals with the Trp194Trp genotype (OR = 0.48; 95% CI, 0.27–0.86) and the Arg194Trp
genotype (OR = 0.79; 95% CI, 0.60–1.05) compared with those with the Arg194Arg genotype.
Compared with those with the Arg399Arg genotype, the risk for NPC was not significantly
different in individuals with the Arg399Gln genotype (OR = 0.82; 95% CI, 0.62–1.08) and the
Gln399Gln genotype (OR = 1.20; 95% CI, 0.69–2.06). Further analyses stratified by gender and
smoking status revealed a significantly reduced risk of NPC among males (OR = 0.32; 95% CI, 0.14–
0.70) and smokers (OR = 0.34; 95% CI, 0.14–0.82) carrying the XRCC1 194Trp/Trp genotype
compared with those carrying the Arg/Arg genotype. No association was observed between
Arg399Gln variant genotypes and the risk of NPC combined with smoking and gender.
Conclusion: Our findings suggest that the XRCC1 Trp194Trp variant genotype is associated with
a reduced risk of developing NPC in Cantonese population, particularly in males and smokers.
Larger studies are needed to confirm our findings and unravel the underlying mechanisms.
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Background
Nasopharyngeal carcinoma (NPC) is one of the most
common cancers in the Cantonese population in south-
ern China [1]. Etiological factors include Epstein-Barr
virus infection, tobacco smoking, and consumption of
salted fish [2-4]. In addition to environmental factors,
genetic factors such as chromosomal aberrations, nucle-
otide polymorphisms of HLA class I and II alleles, glutath-
ione S-transferase M1, and cytochrome P450 2E1 also
play a role in the development of NPC [5-9]. Only a few
people develop the disease in areas where NPC is endemic
even though everyone is exposed to the same environ-
ment, suggesting that genetic differences such as single
nucleotide polymorphisms (SNP) may contribute to NPC
carcinogenesis.
Polymorphisms in XRCC1 have been identified at con-
served sites, including two SNPs at codons 194 (Arg to
Trp) and 399 (Arg to Gln) [10]. These findings suggest
that since XRCC1 is essential for removing endogenous
and exogenous DNA damage, the Arg399Gln substitution
may result in deficient DNA repair [11,12]. On the other
hand, the Trp194 allele seemed to be protective against
DNA damage, although no significant difference was
observed from wild-type in terms of DNA repair capacity.
Molecular epidemiological studies investigating the
Arg194Trp and Arg399Gln variants of XRCC1 and their
impact on cancer risk have generated inconsistent results.
The Arg194 allele is associated with an increased risk of
gastric cardia cancer (adjusted OR = 1.86, 95% CI, 1.09–
3.20), and the Gln399 allele is associated with an
increased risk of gastric cancer (adjusted OR = 1.53, 95%
CI, 0.98–2.39) [13]. Olshan et. al. reported a weak
increase in the risk of head and neck cancer associated
with the Arg194Trp polymorphism (OR = 1.3, 95% CI,
0.6–2.9) and a decreased risk for the Arg399Gln polymor-
phism (OR = 0.6; CI = 0.4–1.1) [14]. Other studies have
reported that these two XRCC1 variants are associated
with elevated risks of esophageal cancer [15], pancreatic
adenocarcinoma [16], and breast cancer [17].
In the present study, we investigated the association
between the Arg194Trp and Arg399Gln variants of
XRCC1, smoking status, and the risk of developing NPC
in the Cantonese population living in southern China.
Methods
Study subjects
The study group consisted of 462 patients with histologi-
cally confirmed, untreated NPC and 511 cancer-free con-
trols. All subjects were ethnic Cantonese living in
southern China. The NPC patients were consecutively
recruited from February 2000 to September 2003 at Sun
Yat-Sen University Cancer Center (Canton). Disease stag-
ing was performed in accordance with the China 92 TNM
staging system [18]. Population controls were selected
from a community screening program for early detection
of cancer. For each eligible case, we tried to match one
control subject by age (± 5 years) and ethnicity (Canton-
ese). At recruitment, informed consent was obtained from
each subject and each participant was then interviewed to
solicit detailed information on demographic characteris-
tics and lifetime history of tobacco use. Overall, 520 eligi-
ble cases and 520 eligible controls agreed to further risk
factor interviews administered by a trained nurse-inter-
viewer, with the final study consisting of 462 cases (88.8%
of eligible) and 511 controls (98.3% of eligible) due to
lack of information on smoking and the inability to col-
lect blood from some subjects. Information was collected
on the number of cigarettes smoked per day, the age at
which the subjects started smoking, and the age at which
ex-smokers stopped smoking. Pack-years smoked was cal-
culated to indicate cumulative cigarette dose [pack-years =
(cigarettes per day/20) × (years smoked)]. Smokers were
considered current smokers if they had smoked up to 1
year before the date of cancer diagnosis (or up to the date
of the interview for controls). This study was approved by
the Hospital Review Board of Sun Yat-Sen University Can-
cer Center.
XRCC1 genotyping
Genomic DNA was isolated from peripheral blood and
XRCC1 genotypes at the Arg194Trp and Arg399Gln sites
were determined by PCR-based restriction fragment
length polymorphism as described by Xing et. al. [15]. The
primers for the XRCC1 Arg194Trp polymorphism were 5'
GCC AGG GCC CCT CCT TCA A 3' and 5' TAC CCT CAG
ACC CAC GAG T 3', which generate a 485 bp fragment.
The primers for the XRCC1 Arg399Gln polymorphism
were 5'TCC TCC ACC TTG TGC TTT CT 3' and 5' AGT AGT
CTG CTG GCT CTG GG 3', which generate a 517 bp frag-
ment. PCR was performed in a 25 μl reaction mixture con-
taining approximately 100 ng DNA, 1.0 μM each primer,
0.2 mM each dNTP, 2.0 mM MgCl2, 1.0 U Taq DNA
polymerase with 1 × reaction buffer (Promega, Madison,
WI), and 2% dimethyl sulfoxide. Amplification of the
Arg194Trp site was carried out under the following condi-
tions: an initial melting step of 2 min at 95°C, followed
by 35 cycles of 30 s at 94°C, 30 s at 57°C, and 45 s at
72°C, and a final elongation of 7 min at 72°C. The reac-
tion conditions for the Arg399Gln site were identical
except that the annealing temperature was 61°C.
The restriction enzymes PvuII  and  BcnI  (New England
Biolabs, Beverly, MA) were used to distinguish the
Arg194Trp and Arg399Gln polymorphisms, respectively.
The wild-type Arg194Trp allele generates a single band
representing the entire 485 bp fragment and the variant
194Trp allele generates 396 and 89 bp fragments. At theBMC Cancer 2006, 6:167 http://www.biomedcentral.com/1471-2407/6/167
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Arg399Gln site, the wild-type allele (Arg/Arg) generates 2
DNA bands (384 and 133 bp), the variant allele (Gln/
Gln) has a single 517 bp fragment, and the heterozygote
(Arg/Gln) displays all 3 bands (517, 384, and 133 bp).
The restriction products were analyzed by electrophoresis
on a 2% agarose gel containing ethidium bromide. To ver-
ify the results, 15% of the samples were randomly selected
for duplicate analyses for 63 cases and 74 controls for the
codon 194 polymorphism, and for 64 cases and 75 con-
trols for the codon 399 polymorphism. The genotyping
results were concordant with all duplicate samples.
Statistical analysis
The Hardy-Weinberg Equilibrium was tested to compare
the observed and expected genotype frequencies among
cases and controls, respectively. χ2  tests were used to
examine the differences in genotype distributions
between cases and controls. The associations between
XRCC1 polymorphisms and risk of NPC were estimated
by odds ratios (OR) and their 95% confidence intervals
(CI), which were calculated by unconditional logistic
regression. The ORs were adjusted for age, gender, and
smoking status. All analyses were performed using the Sta-
tistical Analysis System (Version. 6.12, SAS Institute, Cary,
NC). Bonferroni's correction of P-value was evaluated
when multiple comparison analysis was used.
Results
A total of 462 NPC cases and 511 controls were recruited
for the present study. All subjects were ethnic Cantonese.
The age ranges of the NPC patients (45.9 ± 12.2 years) and
the control subjects (45.7 ± 15.6 years) did not differ (P =
0.22, Chi-square test) and no significant differences
between cases and controls in the frequency matched var-
iable age were observed at the time of the interview. Of
these recruited subjects, 417 NPC cases and 495 controls
were eligible for testing at the 194Arg/Trp site, whereas
425 NPC cases and 501 controls were eligible for testing
at the 399Arg/Gln site. We did not observe a higher male/
female ratio in NPC cases than in controls. The NPC
patients consumed fewer cigarettes (16.1 pack-years) than
did controls (22.8 pack-years; P = 0.04, Chi-square test);
the median cigarette consumption was 20 pack-years in
both groups. Age, gender and smoking status of the NPC
cases and the controls are summarized in Table 1.
XRCC1 polymorphisms and NPC risk
Genotyping (Table 2) showed that the frequencies of the
XRCC1 194Arg and 194Trp alleles were 69.0% and 31.0%
among controls, respectively, and 76.0% and 24.0%
among NPC patients. The distribution of XRCC1
Arg194Trp genotypes among controls (Arg/Arg, 47.5%;
Arg/Trp, 43.8%; Trp/Trp, 8.7%) was consistent with val-
ues predicted by the Hardy-Weinberg equilibrium (P =
0.85, Chi-square test). The frequencies of these three gen-
otypes among NPC patients (Arg/Arg, 55.7%; Arg/Trp,
39.8%; and Trp/Trp, 4.5%) were significantly different
from controls (P = 0.009, Chi-square test). The distribu-
tion of the Arg/Arg, Arg/Gln and Gln/Gln genotypes at the
Arg399Gln site among controls was 53.9%, 40.1% and
6.0%, which was in accordance with the Hardy-Weinberg
equilibrium (P = 0.72, Chi-square test). The distribution
of these Arg399Gln genotypes among NPC patients
(56.7%, 35.8% and 7.5%, respectively) did not differ
from the controls (P > 0.05, Chi-squared test).
For the XRCC1  Arg194Trp polymorphism, individuals
with the XRCC1 Trp194Trp genotype had a nearly 0.50-
fold decreased risk of developing NPC compared to those
with the Arg194Arg genotype (OR = 0.48; 95% CI, 0.27–
0.86, P = 0.01); the risk for developing NPC for individu-
als with the Arg/Trp genotype did not appear to differ sig-
nificantly (OR = 0.79; 95% CI, 0.60–1.05). For the XRCC1
Arg399Gln polymorphism, the risk for developing NPC
did not differ between individuals with the Arg/Arg geno-
type and those with the Arg/Gln genotype (OR = 0.82;
95% CI, 0.62–1.08) or the Gln/Gln genotype (OR = 1.20;
95% CI, 0.69–2.06)(Table 2). Since the gender frequency
was not matched between the groups, we further analyzed
the association between the XRCC1  Arg194Trp and
Arg399Gln polymorphisms and the risk of developing
NPC by gender. Multivariate regression analyses showed
that males carrying the XRCC1 194Trp/Trp genotype had
a reduced risk of developing NPC (OR = 0.32; 95% CI,
0.14–0.70; P = 0.004) compared with those carrying the
Arg/Arg genotype; risk in males was not effected by the
194Arg/Trp heterozygous genotype (OR = 0.77; 95% CI,
0.54–1.10). No association between XRCC1 Arg194Trp
variant genotype and the risk of developing NPC was
found in females. The OR values were 0.78 (95% CI,
0.46–1.33) and 1.11 (95% CI, 0.47–2.61), respectively,
for the XRCC1  194Arg/Trp and 194Trp/Trp genotypes.
Moreover, there was also no association between
Arg399Gln variant genotype and the risk of developing
NPC in either males or females (Table 3).
The association of XRCC1 Arg194Trp and Arg399Gln pol-
ymorphisms and the risk of developing NPC was then
analyzed by smoking status. Among smokers, subjects car-
rying the XRCC1 194Trp/Trp genotype had an OR of 0.34
(95% CI, 0.14–0.82; P = 0.01), which was significantly
lower than the OR among nonsmokers carrying the Trp/
Trp genotype (OR = 0.77; 95% CI, 0.35–1.70) or the Arg/
Trp genotype (OR = 0.73; 95% CI, 0.48–1.11) (P < 0.01,
test for homogeneity). However, no association between
Arg399Gln variant genotype and the risk of developing
NPC in either smokers or nonsmokers was observed in
this study (Table 4).BMC Cancer 2006, 6:167 http://www.biomedcentral.com/1471-2407/6/167
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We examined the association between XRCC1 Arg194Trp
and Arg399Gln polymorphisms and the risk of develop-
ing NPC by age. Though the subjects more than 60 years
old carrying the XRCC1 194 Trp/Trp or Arg/Trp genotype
had lower ORs of 0.27 (95% CI, 0.03–2.52) and 0.48
(95% CI, 0.23–0.99), respectively; the P-value was not sig-
nificant after Bonferroni's correction. Similar results were
also obtained from the analysis of the association
between the XRCC1 Arg194Trp polymorphism and the
risk of developing NPC in subjects less 60 years old. No
association between the Arg399Gln variant genotype and
the risk of developing NPC was observed in either age
group (Table 5).
Discussion
Humans have developed complex DNA repair systems to
defend against the harmful consequences of DNA damage
and safeguard the integrity of the genome. The human
XRCC1 gene, which encodes a protein that plays a central
role in the single-strand break repair or base excision
repair pathway [19], was identified by its ability to restore
DNA repair and mapped to the long arm of chromosome
19q13 [20]. The gene encodes XRCC1 and three other
DNA repair enzymes: DNA ligase I at its 3' end, DNA
polymerase  β, and polyadenosine diphosphate (ADP)-
ribose polymerase (PARP), which are involved in the exci-
sion and repair of single-strand breaks and in recombina-
tional repair pathways [21,22].
We observed frequencies of 0.26 for the XRCC1 399Gln
allele and 6.0% for the Gln/Gln genotype, which are very
similar to other studies on Chinese populations [23,24]
but significantly lower than those reported for a Cauca-
sian population (0.335 and 11.5%, respectively, n = 1240;
P < 0.05) [25]. Studies of associations between the poly-
morphisms and cancer risk have been inconsistent, possi-
Table 1: Characteristics of age, gender and smoking status of cases and controls
Variable Cases(n = 462) Controls (n = 511)
Gender
Male 339 (73.4)a 252 (49.1)
Female 123 (26.6)a 259 (50.9)
Age range (yr)
<60 395 (85.5)b 422 (82.6)
≥60 67 (14.5)b 89 (17.4)
Mean age in years (S. D.) 45.9 (12.2) 45.7 (15.6)
Smoking statusa
No 164 (35.5)c 353 (69.1)
Yes 298 (64.5)c 158 (30.9)
Pack-years smoked
<20 103 (34.6)d 70 (44.3)
≥20 195 (65.4)d 88 (55.7)
Mean pack-years smoked (S.D.) 16.1 (17.2) 22.8 (17.3)
Median pack-years smoked (S.D.) 20 (15.6) 20 (17.3)
aP = 0.0000, χ2 = 58.85; bP = 0.22, χ2 = 1.53; cP = 0.0000, χ2 = 109.77; dP = 0.04, χ2 = 4.15
Table 2: Association between risk of NPC and XRCC1 genotypes among cases and controls
Genotype Cases No. (%)a Controls No. (%)b Unadjusted OR Adjusted ORc (95%CI) P value
XRCC1 Arg194Trp
Arg/Arg 232(55.7) 235 (47.5) 1.00 1.00
Arg/Trp 166(39.8) 217(43.8) 0.80 0.79(0.60–1.05) 0.10
Trp/Trp 19(4.5) 43(8.7) 0.48 0.48(0.27–0.86) 0.01*
Allele of Trp 0.24 0.31
XRCC1 Arg399Gln 
Arg/Arg 241(56.7) 270(53.9) 1.00 1.00
Arg/Gln 152(35.8) 201(40.1) 0.81 0.82(0.62–1.08) 0.16
Gln/Gln 32(7.5) 30(6.0) 1.20 1.20(0.69–2.06) 0.53
Allele of Gln 0.25 0.26
a 417 cases and 495 controls were eligible tested in condon 194 genotype variant.
b 425 cases and 501 controls were eligible tested in condon 399 genotype variant.
c Adjusted OR were calculated with the XRCC1 194Arg/Arg or 399Arg/Arg genotype as the reference group and adjusted for age, sex, smoking 
status.
*P-value remained significant after Bonferroni's correction.BMC Cancer 2006, 6:167 http://www.biomedcentral.com/1471-2407/6/167
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bly because of linkage disequilibrium with a determinant
variant of the XRCC1 gene [26]. A close linkage between
the 194Trp and 399Arg alleles was previously reported in
the Chinese population [27].
This pilot study analyzed two polymorphisms of the
XRCC1 gene in relation to the risk of NPC: the amino acid
substitutions Arg to Trp at codon 194 and Arg to Gln at
codon 399. Arg194Trp resides in the linker region separat-
ing the DNA polymerase β domain from the PARP-inter-
acting domain and Arg399Gln residues in the breast
cancer susceptibility gene 1 product carboxyl-terminus
domain. Both are likely to affect the function of the
XRCC1 protein. Chinese hamster ovary cell lines with
mutations in XRCC1 have a reduced ability to repair sin-
gle-strand DNA breaks and are hypersensitive to ionizing
radiation and alkylating agents [28].
To date, there is only one published NPC study reporting
the associations between NPC risk and XRCC1 polymor-
phisms. An OR of 0.64 (95% CI, 0.43–0.96) was observed
among individuals with the Arg280His or His280His gen-
otypes, whereas no association was noted between poly-
morphisms at codon 399 of XRCC1 and disease [29]. In
this study, we observed a lower risk of developing NPC in
individuals with the XRCC1 codon194 Trp/Trp genotype
(OR = 0.48, 95% CI, 0.27–0.86). The protective effect of
the codon 194 Trp allele observed in our study is consist-
ent with several studies of cancers and XRCC1 genotype.
Ratnasinghe et. al. observed a decreased risk of lung can-
cer associated with the presence of at least one variant
allele (OR = 0.7, 95% CI, 0.4–1.2) among Chinese tin
miners [30]. Subjects with a codon 194 Trp allele were
also at decreased risk of squamous cell carcinoma of the
head and neck (OR = 0.8, 95% CI, 0.5–1.3) [31] and blad-
der cancer (OR = 0.6, 95% CI, 0.3–1.0)[32]. However,
there are apparently conflicting data showing that the
Arg194Trp genotype increases the risk of head and neck
cancer (OR = 2.61) [33] and breast cancer [17].
Although several phenotype analysis studies have associ-
ated the 399Gln allele with high levels of DNA adduct for-
mation and increased frequency of sister chromatid
change, we failed to observe any association between the
XRCC1 Arg399Gln polymorphism (alone or in combina-
tion with smoking) and risk of developing NPC. This
Table 4: Association between XRCC1 condon 194 and 399 polymorphisms and NPC risk stratified by smoking status
Genotype Non smoking Smoking
Cases Controls Adjusted ORa (95%CI) P value Cases Controls Adjusted ORa (95%CI) P value
XRCC1 Arg194Trp
Arg/Arg 78 157 1.00 154 78 1.00
Arg/Trp 58 155 0.73(0.48–1.11) 0.14 108 62 0.87(0.57–1.33) 0.52
Trp/Trp 10 29 0.77(0.35–1.70) 0.52 9 14 0.34(0.14–0.82) 0.017*
XRCC1 Arg399Gln 
Arg/Arg 85 185 1.00 156 85 1.00
Arg/Gln 50 140 0.73(0.47–1.12) 0.14 102 60 0.90(0.59–1.38) 0.62
Gln/Gln 11 18 1.42(0.63–3.23) 0.40 21 12 0.91(0.41–1.99) 0.81
aAdjusted OR were calculated with the XRCC1 194Arg/Arg or 399Arg/Arg genotype as the reference group and adjusted for age, sex.
* P-value remained significant after Bonferroni's correction.
Table 3: Association between XRCC1 condon 194 and 399 polymorphisms and NPC risk stratified by gender
Genotype Male Female
Cases Controls Adjusted ORa (95% CI) P value Cases Controls Adjusted ORa (95% CI) P value
XRCC1 Arg194Trp
Arg/Arg 175 120 1.00 57 115 1.00
Arg/Trp 121 106 0.77(0.54–1.10) 0.16 45 111 0.78(0.46–1.33) 0.36
Trp/Trp 10 21 0.32(0.14–0.70) 0.004* 9 22 1.11(0.47–2.61) 0.82
XRCC1 Arg399Gln 
Arg/Arg 177 130 1.00 64 140 1.00
Arg/Gln 114 105 0.81(0.57–1.15) 0.24 38 95 0.82(0.47–1.43) 0.48
Gln/Gln 22 15 1.04(0.52–2.11) 0.91 10 15 1.28(0.49–3.36) 0.62
aAdjust OR were calculated with the XRCC1 194Arg/Arg or 399Arg/Arg genotype as the reference group and adjusted for age, smoking.
* P-value remained significant after Bonferroni's correction.BMC Cancer 2006, 6:167 http://www.biomedcentral.com/1471-2407/6/167
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result is generally consistent with previous findings for
lung cancer [25], bladder cancer [34], esophageal cancer
[15], and malignant lymphoma [35]. However, there are
again conflicting data in the literature. For example, this
polymorphism has previously been shown to be a risk fac-
tor for lung cancer [36] and head and neck cancer [31] in
smokers, yet it has also been shown to be protective for
bladder cancer [32], pancreatic adenocarcinoma [16], and
gastric cardia cancer [37]. The conflicting results may stem
from the complexity etiology of cancer with regard to
exposure to carcinogens, DNA repair genotypes or other
genetic factors, and the small sample size.
Cigarette smoke is a major cause of a variety of malignan-
cies including cancers of the larynx, oral cavity and phar-
ynx, esophagus, bladder, and lung. Numerous studies
have consistently shown that cigarette smoke may play an
important role as an environmental etiological factor in
the development of NPC in China [2,38]. Cigarette smoke
contains a myriad of genotoxic agents and carcinogens
such as nitrosamine 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone (NNK). XRCC1 399Gln/Gln genotype
carriers reportedly have a decreased capacity for repair of
NNK-induced sister chromatid exchange [11,39].
Although the biochemical and biological characteristics of
these XRCC1 variants have not been fully determined,
Lunn et al. [40] reported that the XRCC1 399Gln allele
was significantly associated with higher levels of placental
aflatoxin B1-DNA adducts and glycophorin A somatic
mutations. In this study, we observed a significant protec-
tive influence of the XRCC1 194Trp/Trp genotype (OR =
0.34, 95% CI, 0.14–0.82) on NPC risk in smokers, sug-
gesting effect modification by tobacco smoking. The
results of the present study are generally consistent with
previous findings in a relatively large lung cancer study,
which showed a protective effect of the XRCC1 194Trp
allele against tobacco-related lung cancers (OR = 0.86;
95% CI, 0.77 – 0.95). They also reported that the XRCC1
399Gln/399Gln genotype was associated with a decreased
cancer risk among heavy smokers (OR = 0.71, 95% CI,
0.51–0.99), but an increased cancer risk among light
smokers (OR = 1.38, 95% CI, 0.99 – 1.94) [41]. We also
observed a significantly lower risk of NPC (OR = 0.32;
95% CI, 0.14–0.70) in males carrying the XRCC1 194Trp/
Trp genotype. Laboratory and epidemiologic data have
indicated that men and women react differently to
tobacco and environmental carcinogens [42,43]. Exactly
how cigarette smoking and DNA repair polymorphisms
affect the DNA repair capacity is unknown. One possible
mechanism is that at high levels of exposure, the DNA
repair capacity is saturated even in individuals with a
higher repair capacity [44,45]. Our findings may explain
such a gender difference. The high incidence of NPC in
women cannot be attributed to smoking alone in Chinese
and other Asian populations where smoking among
women is relatively uncommon. Our results suggest that
analysis of germline polymorphisms and epigenetic alter-
ations should be further evaluated in these male popula-
tions, particularly in epidemiologic studies of the risks of
NPC.
Conclusion
In summary, our study suggests that the XRCC1
Trp194Trp variant genotype is associated with a reduced
risk of developing NPC among Cantonese living in south-
ern China. The decrease in risk of NPC associated with
this functional polymorphism was more pronounced
among smokers and males. No association was observed
between the risk of developing NPC and the XRCC1
Arg399Gln polymorphism alone or jointly with smoking,
gender, and age. Because of the limited selection of cases,
our findings should be confirmed in a larger study.
Abbreviations
NPC, nasopharyngeal carcinoma; EBV, Epstein-Barr virus;
CI, confidence interval; OR, odds ratio; GSTM1, Glutath-
ione S-transferase M1; XRCC1, X-ray repair cross comple-
menting group 1.
Table 5: Association between XRCC1 condon 194 and 399 polymorphisms and NPC risk stratified by age range (yr)
Genotype <60 ≥60
Cases Controls Adjusted ORa (95% CI) P value Cases Controls Adjusted ORa (95%CI) P value
XRCC1 Arg194Trp
Arg/Arg 189 190 1.00 42 45 1.00
Arg/Trp 151 179 0.85(0.62–1.16) 0.30 17 38 0.48(0.23–0.99) 0.05*
Trp/Trp 17 37 0.52(0.28–0.96) 0.04 1 6 0.27(0.03–2.52) 0.25
XRCC1 Arg399Gln 
Arg/Arg 210 228 1.00 27 42 1.00
Arg/Gln 131 159 0.83(0.61–1.13) 0.23 25 41 0.84(0.38–1.86) 0.67
Gln/Gln 22 25 1.09(0.58–2.05) 0.79 10 6 1.75(0.48–6.44) 0.40
aAdjust OR were calculated with the XRCC1 194Arg/Arg or 399Arg/Arg genotype as the reference group and adjusted for sex, smoking status.
*P-value was not significant after Bonferroni's correction.BMC Cancer 2006, 6:167 http://www.biomedcentral.com/1471-2407/6/167
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